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The successful development and translation of biomarkers into
clinically actionable results have been well choreographed,
beginning with demonstration of analytical and clinical validity,
followed most importantly with demonstration of clinical utility
[1]. Most current biomarker guidelines for clinical use by physi-
cians, as well as reimbursement decisions by payers, are usu-
ally clear on these evidentiary requirements. Although well
intentioned, the sanctity of this foundational process is consis-
tently challenged by developments, in the laboratory and clinic,
that continue to impede clinical progress and slow treatment
benefit to patients.
This is especially true in oncology, where the biomarker
landscape has changed rapidly and substantially in the past
decade. Increasingly, patient care and treatment decisions are
being driven by biomarkers commonly derived from a simple
venipuncture (liquid biopsy) and not an invasive tissue biopsy
[2]. Convenience, faster turnaround time, easy access to repeat
testing, lower cost, and a more accurate reflection of a tumor’s
heterogeneity, or true biology, have prompted and accelerated
this shift [3, 4]. Furthermore, biomarkers derived from a liquid
biopsy continue to increase in type and number and now
include nucleic acids (both DNA and RNA), proteins, circulating
tumor cells, and fractions of tumor cells (exosomes), as well as
normal cellular elements [5], guaranteeing continued bio-
marker opportunities and application to patient management.
In cancer, cell-free, circulating tumor DNA (ctDNA) is the prin-
ciple mutation-based liquid biopsy biomarker in use today, with
analysis predominantly by next-generation sequencing (NGS), as
well as other technologies [5]. As a class of biomarkers, ctDNA
has demonstrated decision-making potential along the entire
continuum of patient care, from risk identification and early dis-
ease detection through drug targeting and response prediction
in overt ormetastatic disease [6]. The benefits of clinicalmanage-
ment with ctDNA may best manifest in non-small cell lung can-
cer, where discovery of new driver mutations has led to new
drugs and remarkably improved response rates in patients [7, 8].
Moreover, detection of ctDNA in other body fluids, such as urine
and cerebral spinal fluid, further extends its potential diagnostic
applications [9, 10]. This apparent clinical versatility is unprece-
dentedwhen considered alongside past cancer biomarkers.
Unfortunately, this embarrassment of diagnostic riches
in care and treatment of patients with cancer is not without
consequences, encumbered by both technical challenges
and administrative or reporting difficulties. Multiple sources
have previously focused on technical comparisons among
ctDNA technologies and laboratories, with ample evidence
that significant differences in results exist between labs that
question the validity and actionability of a result [11, 12].
At the other end of the diagnostic result spectrum is the
actual report provided to the physician, translating the generated
result into a clinical decision. Importantly, there has been little
standardization in this arena. Indeed, for an average clinician not
well versed in molecular genetics and without access to a sophis-
ticated molecular tumor board, deciphering the results of a
patient’s next-generation sequencing report is akin to trying
to read a novel written in hieroglyphics. In this issue of The
Oncologist, Peng and colleagues present the results of their
clever investigation into laboratories reporting NGS results to cli-
nicians and offering result interpretation and treatment guidance
[13]. Their focus here is much needed because their findings are
alarming and requiremore attention by all stakeholders.
To address reporting practices across laboratories, Peng’s
group simulated (synthesized) ctDNA with known variants
and allelic frequencies and shipped samples to 66 genetic
testing laboratories with a devised case history form included.
The returned reports were reviewed using 21 predefined
criteria designed to reflect detection accuracy, report integ-
rity, and supporting information.
In keeping with previous reports on technical discor-
dance among laboratories, this study also found consider-
able discordance in reporting detected variants, with only
42% (28/66) of respondents scoring complete concordance.
Generating valid results for ctDNA is challenging. Circulating
tumor DNA is a minor component of the total circulating
DNA, estimated in some cases to be as low as 0.01% [5].
The multistep process required to analyze this small fraction
into an actionable result—collecting and processing blood,
extracting the DNA and preparing libraries, generating suffi-
cient sequences from ctDNA strands, and the bioinformatic
interpretation of those sequences—all potentially add error
to the result [5]. The lack of analytically validated controls
and the continued push to identify variants at the extreme
low end of an assay’s range exacerbate this challenge and
explain, in part, these findings [14].
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What was most surprising, and specific to the intent of
this study, is that none of the laboratories scored 100%
against the 21 predefined report criteria, with the majority
of reports scoring between 50 and 70 points out of a total
of 100 points (37/66, 56.0%). Reports from many participating
labs were insufficiently annotated, lacking important informa-
tion regarding technical performance metrics for technologies
employed, quality control results to help guide result interpre-
tation, and detailed clinical interpretation of all variants and
possible drugs, including potential clinical trials as an option to
gain access to a drug. ctDNA testing allows for panels of well
over hundreds of genes to be analyzed simultaneously as a sin-
gle test. Such capability allows exploration of all possible driver
mutations in a patient’s cancer and possible off-label use of a
drug based on a common driver mutation. This biomarker-
enabled therapeutic cross-walking greatly benefits clinical sce-
narios where treatment options are limited [15]. In all, 88% of
participating laboratories lacked sufficient information for ade-
quate interpretation of results and patient management.
This study is not without limitations. Most of the partici-
pating labs were based in China, and detail regarding the par-
ticipating laboratories is minimal, making it difficult to draw
more deeply on the study’s conclusions. However, these limi-
tations, as well as other technical limitations, do not diminish
the significance of their findings, which contribute to a much
bigger, developing message: Translating genomic biomarkers
obtained from liquid biopsies or tissue biopsies into routine
clinical use is far more than just generating a result.
As Peng et al. remind us, demonstrating that a biomarker
has analytical validity, clinical validity, and clinic utility is not
sufficient if the treating physician is not adequately informed
about the interpretation of genotyping results, the implica-
tions and limitations of the results, and possible alternative
treatment options for the patient if the results do not indi-
cate a clear action [13]. Moreover, even though molecular
tumor boards evolved in part to offer such assistance to
treating physicians, they, too, require such guidance from the
laboratory’s report to avoid errors [15]. The interpretation of
genomic signals is not always explicit and can be misleading
[16, 17]. Biology remains one of the biggest challenges to
reducing genotyping to routine practice, and more standards
and guidelines for generating and, as this study indicates,
reporting results are urgently needed.
Fortunately, many professional societies and action groups
are moving in this direction. For example, the plethora of differ-
ent reports from commercial and academic labs, replete with
different reporting elements and styles, can be confusing to
physicians. The College of American Pathologists (CAP) has
made available standardized pathology reporting templates that
can greatly harmonize with the information reported from liq-
uid biopsy results [18], affording accurate and confident deci-
sion making. Moreover, a recent publication from CAP and the
American Society Clinical Oncology critiqued the literature on
published reports for ctDNA, focusing on tissue-based testing
and controlling preanalytic variability in generating results. Their
critical findings and recommendations on evidence generation
are relevant to ctDNA from liquid biopsies as well [19]. Their
recommendations join the chorus for more evidence develop-
ment before introducing a new biomarker or technology into
clinical use. Additionally, efforts are underway to substantiate
commercially available quality control reagents to understand
the true performance characteristics of a laboratory’s ctDNA
testing and allow cross-lab comparison of results and result
interpretation [20].
What remains to be developed and implemented is a con-
sensus on reporting requirements to complete the translation
of biology to precision medicine. The wealth of potential bio-
markers obtained through liquid biopsies appears endless. It is
not too late to set the record straight.
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Editor’s Note:
See the related article, “From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for
Next-Generation Sequencing-Based Circulating Tumor DNA Analysis,” by Rongxue Peng, Rui Zhang, Martin P. Horan
et al., on page 218 of this issue.
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